What happened
SK biopharmaceuticals filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$174M (+40.3% year on year), operating profit of US$68.3M (+56.9% year on year) and net income of US$59.9M (+188.1% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$174M |
|---|---|
| Revenue vs a year earlier | +40.3% |
| Operating profit | US$68.3M |
| Net income | US$59.9M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-05, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260805800117 → open original filing |
Source: DART. Information only, not investment advice.